Tailoring Myopic CNV Treatment Based on Preexisting Ophthalmic Condition

Affiliations

¹ Department of Medicine McGill University, Montréal, Québec, Canada 2Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada.
² Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada 4Departments of Pediatrics and Ophthalmology, Centre Hospitalier Unive.

Comment

Tianwei Ellen Zhou et al. Invest Ophthalmol Vis Sci. 2015 Dec.

. 2015 Dec;56(13):8362-3.

doi: 10.1167/iovs.15-18314.

¹ Department of Medicine McGill University, Montréal, Québec, Canada 2Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada.
² Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada 3Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, Québec, Canada 4Departments of Pediatrics and Ophthalmology, Centre Hospitalier Unive.

No abstract available

Comment in

Choroidal Response to Anti-VEGF Therapy in Subgroups Classified by Preexisting Ophthalmic or Systemic Condition.
Ahn SJ, Park KH, Woo SJ. Ahn SJ, et al. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8364. doi: 10.1167/iovs.15-18634. Invest Ophthalmol Vis Sci. 2015. PMID: 26747766 No abstract available.

Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ, Park KH, Woo SJ. Ahn SJ, et al. Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5794-800. doi: 10.1167/iovs.14-16006. Invest Ophthalmol Vis Sci. 2015. PMID: 26325418